Human ANP infusion decreased mean arterial blood pressure by 4 mmHg (P<0.01) and increased lipid oxidation rates by 15% (P<0.05) compared with placebo during the postprandial phase.
RCT (n=12)
double-blind
randomized, cross-over
Does ANP infusion increase postprandial lipid oxidation and energy expenditure while decreasing arterial blood pressure in men?
ANP infusion regulates postprandial lipid oxidation, energy expenditure, and arterial blood pressure, identifying a novel metabolic pathway with potential therapeutic implications.
Mean Difference: -4
p-value: p=<0.01
OBJECTIVE: Atrial natriuretic peptide (ANP) regulates arterial blood pressure. In addition, ANP has recently been shown to promote human adipose tissue lipolysis through cGMP-mediated hormone-sensitive lipase activation. We hypothesized that ANP increases postprandial free fatty acid (FFA) availability and energy expenditure while decreasing arterial blood pressure. RESEARCH DESIGN AND METHODS: We infused human ANP (25 ng . kg(-1) . min(-1)) in 12 men (age 32 +/- 0.8 years, BMI 23.3 +/- 0.4 kg/m(2)) before, during, and 2 h after ingestion of a standardized high-fat test meal in a randomized, double-blind, cross-over fashion. Cardiovascular changes were monitored by continuous electrocardiogram and beat-by-beat blood pressure recordings. Metabolism was monitored through venous blood sampling, intramuscular and subcutaneous abdominal adipose tissue microdialysis, and indirect calorimetry. RESULTS: ANP infusion decreased mean arterial blood pressure by 4 mmHg during the postprandial phase (P < 0.01 vs. placebo). At the same time, ANP induced lipolysis systemically (P < 0.05 vs. placebo) and locally in subcutaneous abdominal adipose tissue (P < 0.0001 vs. placebo), leading to a 50% increase in venous glycerol (P < 0.01) and FFA (P < 0.05) concentrations compared with placebo. The increase in FFA availability with ANP was paralleled by a 15% increase in lipid oxidation rates (P < 0.05 vs. placebo), driving a substantial increase in postprandial energy expenditure (P < 0.05 vs. placebo). CONCLUSIONS: Our data identify the ANP system as a novel pathway regulating postprandial lipid oxidation, energy expenditure, and concomitantly arterial blood pressure. The findings could have therapeutic implications.
Birkenfeld et al. (Sat,) reported a rct. Human atrial natriuretic peptide (ANP) vs. Placebo was evaluated on Mean arterial blood pressure during the postprandial phase (-4 mmHg, p=<0.01). Human ANP infusion decreased mean arterial blood pressure by 4 mmHg (P<0.01) and increased lipid oxidation rates by 15% (P<0.05) compared with placebo during the postprandial phase.